Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

Dow Jones12-29 23:42

By Colin Kellaher

Shares of Praxis Precision Medicines rose sharply on Monday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for its drug candidate for essential tremor.

Praxis on Monday said the FDA granted breakthrough-therapy designation to ulixacaltamide for people with the nervous-system condition that causes rhythmic shaking that they can't control.

Analysts at Truist, who have a buy rating and $500 price target on Praxis shares, said the designation is incrementally positive and derisking for the Boston company's essential-tremor program.

The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies.

Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026.

Praxis shares were recently changing hands at $300.74, up nearly 13%.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 29, 2025 10:42 ET (15:42 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595739210?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 23:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595739210","market":"us","top_or_hot":-1,"title":"Praxis Shares Rise on Ulixacaltamide Breakthrough Designation","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> rose sharply on Monday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for its drug candidate for essential tremor. \n</p>\n<p>\n  Praxis on Monday said the FDA granted breakthrough-therapy designation to ulixacaltamide for people with the nervous-system condition that causes rhythmic shaking that they can't control. \n</p>\n<p>\n  Analysts at Truist, who have a buy rating and $500 price target on Praxis shares, said the designation is incrementally positive and derisking for the Boston company's essential-tremor program. \n</p>\n<p>\n  The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies. \n</p>\n<p>\n  Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026. \n</p>\n<p>\n  Praxis shares were recently changing hands at $300.74, up nearly 13%. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 29, 2025 10:42 ET (15:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Shares Rise on Ulixacaltamide Breakthrough Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Shares Rise on Ulixacaltamide Breakthrough Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-29 23:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> rose sharply on Monday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for its drug candidate for essential tremor. \n</p>\n<p>\n  Praxis on Monday said the FDA granted breakthrough-therapy designation to ulixacaltamide for people with the nervous-system condition that causes rhythmic shaking that they can't control. \n</p>\n<p>\n  Analysts at Truist, who have a buy rating and $500 price target on Praxis shares, said the designation is incrementally positive and derisking for the Boston company's essential-tremor program. \n</p>\n<p>\n  The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies. \n</p>\n<p>\n  Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026. \n</p>\n<p>\n  Praxis shares were recently changing hands at $300.74, up nearly 13%. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 29, 2025 10:42 ET (15:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2595739210","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595739210","pubTimestamp":1767022920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Praxis Precision Medicines rose sharply on Monday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for its drug candidate for essential tremor.Praxis on Monday said the FDA granted breakthrough-therapy designation to ulixacaltamide for people with the nervous-system condition that causes rhythmic shaking that they can't control.Analysts at Truist, who have a buy rating and $500 price target on Praxis shares, said the designation is incrementally positive and derisking for the Boston company's essential-tremor program.The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies.Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026.Praxis shares were recently changing hands at $300.74, up nearly 13%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Praxis股价因Ulixacaltamide突破性认定而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Shares of Praxis Precision Medicines rose sharply on Monday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for its drug candidate for essential tremor. \n\n\n  Praxis on Monday said the FDA granted breakthrough-therapy designation to ulixacaltamide for people with the nervous-system condition that causes rhythmic shaking that they can't control. \n\n\n  Analysts at Truist, who have a buy rating and $500 price target on Praxis shares, said the designation is incrementally positive and derisking for the Boston company's essential-tremor program. \n\n\n  The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies. \n\n\n  Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026. \n\n\n  Praxis shares were recently changing hands at $300.74, up nearly 13%. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 29, 2025 10:42 ET (15:42 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595739210","isCrawlerRequest":true}